BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delanian, S
Right arrow Articles by Lefaix, J-L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delanian, S
Right arrow Articles by Lefaix, J-L
British Journal of Radiology 75 (2002),467-469 © 2002 The British Institute of Radiology

Short communication

Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate

S Delanian, MD, PhD 1 and J-L Lefaix, PhD 2

1 Service d'Oncologie-Radiothérapie, Hôpital Saint-Louis APHP, 1 Ave Claude Vellefaux, 75010 Paris and 2 Laboratoire de Radiotoxicologie, CEA-DSV-DRR, BP12, 91680 Bruyères-Le-Chatel, France

Osteoradionecrosis (ORN) is a late terminal sequela of irradiation that does not resolve spontaneously. In a preliminary study, a combination of pentoxifylline (PTX), tocopherol (Vit-E) and clodonate has been shown to be of clinical benefit with more than 50% regression of progressive ORN observed at 6 months in 12 patients. A 68-year-old woman presenting with severe exteriorized osteoradionecrosis had received radiotherapy for breast cancer 29 years previously. She had palpable breast fibrosis, including the sternum (15 cm x 11 cm) and a painful fistulous track in the upper part of the bone (orifice diameter 10 mm) surrounded by local inflammatory signs, and chronic osteitis with sequestra extrusion. MRI showed deep radiation-induced fibrosis below this area without cancer recurrence, and complete bone destruction over an area of 7 cm x 4 cm. Oral PTX (800 mg day-1), Vit.E (1000 IU day-1) and clodronate (1600 mg day-1) were administered daily for 3 years and were well tolerated. The patient exhibited regular clinical improvement until complete closure of the fistula and total regression of the clinical fibrosis. MRI confirmed the good response and showed heterogeneous restoration of the sternum, which was filled with new tissue. This is the first time that antifibrotic treatment with combined PTX–Vit.E plus clodronate has been shown to have a significant effect on necrosis, by completely reversing severe progressive ORN and the associated radiation-induced fibrosis.




This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
V Haydont, C Bourgier, and M-C Vozenin-Brotons
Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity
Br. J. Radiol., September 1, 2007; 80(Special_Issue_1): S32 - S40.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
T. B Chiao and A. J Lee
Role of Pentoxifylline and Vitamin E in Attenuation of Radiation-Induced Fibrosis
Ann. Pharmacother., March 1, 2005; 39(3): 516 - 522.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
C Georges, J-L Lefaix, and S Delanian
Resolution of symptomatic epidural fibrosis following treatment with combined pentoxifylline-tocopherol
Br. J. Radiol., October 1, 2004; 77(922): 885 - 887.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Delanian, R. Porcher, S. Balla-Mekias, and J.-L. Lefaix
Randomized, Placebo-Controlled Trial of Combined Pentoxifylline and Tocopherol for Regression of Superficial Radiation-Induced Fibrosis
J. Clin. Oncol., July 1, 2003; 21(13): 2545 - 2550.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2002 by the British Institute of Radiology.